부산대학교 도서관

The biliary excretion of AB-206 was studied in six patients with common bile duct drainage for cholelithiasis and one with PTC-drainage for gallbladder carcinoma. AB-206 was administered orally 30 minutes after the breakfast. The concentration of the drug in bile was determined by the cup method using E. coli Kp strain.After a single oral administration of 500 mg of AB-206, average biliary levels (N=7) were 0, 2.5±3.7, 3.5±4.5, 3.3±3.9, 5.0±3.3, 14.0±25.8, 9.0±16.5, 5.3±7.7, 3.0±3.0, 1.7±2.0, 1.4±1.7, 2.2±4. 2, and 0.2±0. 6μg/ml, whereas with 1, 000 mg (N=6), 7.5±13.1, 34.6±37.6, 41.3±45.2, 36.3±41.4, 33.4±36.0, 31.6±45.4, 28.0±47.1, 25.4±43.8, 12.7±18.7, 6.2±6.9, 1.9±1.2, 1.2±1.0 and 0.4±0.6μg/ml at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 24 hours, respectively.The highest peak was 71.9μg/ml in the former and 123. 9μg/ml in the latter. A doseresponse curve was found in all cases.No definite correlation was found between the biliary excretion of the drug and the liver functions. However, in a PTC-drainage case with jaundice (total bilirubin: 11 mg/dl) the biliary excretion was slightly delayed.Seven cases with surgical infection treated with AB-206 were presented.